Cargando…
Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments
INTRODUCTION: Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It inhibits two of the most common ALK-mutants that confer resistance to crizotinib. Ceritinib was approved by Food and Drug Administration in April 2014. However, the efficacy of ceritinib in Asian patients h...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142169/ https://www.ncbi.nlm.nih.gov/pubmed/28018791 http://dx.doi.org/10.1186/s40064-016-3674-3 |